Bintai Kinden Corporation Berhad is collaborating with Institut Jantung Negara (IJN) on Covid-19 vaccine development in Malaysia.
This cooperative agreement with IJN was established following the Company’s Memorandum of Understanding with the National Heart Institut in September 2020.
Bintai Kinden will be responsible for the introduction of the Covid-19 vaccine in Malaysia while IJN will perform and lead the
clinical tests of the vaccine as required by the Health Ministry under the agreement.
The collaboration was based on an existing partnership between the Bintai Kinden’s subsidiary Bintai Healthcare Sdn Bhd (BHSB), Generex Biotechnology Corp (Generex) and NuGenerex Immuno-Oncology Inc to advance the commercialization of Covid-19 vaccine in Malaysia.
“After Generex has received the full Food and Drug Administration (FDA) approval on the vaccine and provides full documentation to BHSB, BHSB will commence the registration process to National Pharmaceutical Regulatory Agency (NPRA) of Malaysia for the vaccine,” Azri Azerai, Executive Director of Bintai Kinden said.
Bintai Kinden handed over a RM100,000 mock cheque as the initial grant to IJN through the establishment of Bintai Healthcare-IJN Covid 19 Research Grant to fund the necessary research programs today.
